LARRY PIERCE: Open Payments
NPI 1689987042 · MANHATTAN, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,452 in 62 payments from 24 companies in 2025. Trend: 2023 $490 · 2024 $889 · 2025 $1,452
Food & beverage: $1,452
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $387 |
| ABBVIE INC. | 8 | $146 |
| Alkermes, Inc. | 5 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| Lundbeck LLC | 4 | $83 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Novo Nordisk Inc | 3 | $52 |
Products named: AIRSUPRA, REXULTI, ARISTADA, CAPLYTA, FARXIGA, JARDIANCE, VRAYLAR, FANAPT.
Industry payments across KS — which companies pay providers there.
